Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enlicitide Bioavailability Study in Healthy Adults
NCT07481708Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2026
- Primary completion
- May 2026
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 1
01
Overview
Phase 1 trial of enlicitide in hypercholesterolemia (3 arms), sponsored by Merck & Co. Primary endpoints: Area Under the Concentration-Time Curve from Time 0 to Last up to 50 days, Area Under the Concentration-Time Curve from Time 0 to Infinity up to 50 days and 1 more. Started Mar 2026; status: completed.
02
Drugs
enlicitide
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT07481708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07481708.